Tislelizumab & Tremelimumab Among Latest Filings In EU

The sponsors of two monoclonal antibody products, tislelizumab and tremelimumab, are each seeking marketing approval for more than one indication.

Wooden blocks with the word Review. Customer review concept. Reviewing, auditing, reviewer. Service rating. Feedback.
EU marketing applications for new drugs are under review • Source: Alamy

The European Medicines Agency has begun reviewing a number of new drugs for potential pan-EU marketing authorization including Novartis/BeiGene’s tislelizumab for treating both esophageal cancer and non-small cell lung cancer (NSCLC).

Tislelizumab, an anti-PD-1 monoclonal antibody, is already approved in China in seven indications. A biologics license application (BLA) seeking US...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography